UNSPSC 51112522: Sarcolysin

This classification denotes a nitrogen mustard compound with the molecular formula C13H18Cl2N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A960M0G5TP, chemically known as l-phenylalanine, 4-(bis(2-chloroethyl)amino)- but more generally known as sarcolysin, which bears US NIH Compound Identifier 4053. European Medicines Agency schedules Sarcolysin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10448MIG.

UNSPSC 51112522 Sarcolysin is a Commodity code capturing pharmaceutical products—specifically the chemotherapy agent sarcolysin—procured through state and local health agencies. The recent solicitation activity shows state health and human services commissions acquiring sarcolysin and related therapeutics not through traditional vendor purchase orders but through direct-to-manufacturer pharmacy benefit arrangements designed to bypass standard pharmacy benefit manager and group purchasing organization intermediaries. This represents a shift in how state Medicaid and employee health plans source and fulfill prescription medications, moving toward negotiated net pricing models with manufacturers rather than rebate-based structures.

The Texas Health and Human Services Commission posted Request for Information No. HHS0017013 on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The RFI targets vendors with experience executing direct contracts for self-insured employers and government health plans within the past two years, negotiating value-based or outcomes-based agreements, and fulfilling prescription volume requirements outside traditional PBM and GPO relationships. As an exploratory procurement mechanism rather than a binding solicitation, the RFI is designed to inform Texas HHS's future contracting strategy and program design before issuing a formal RFP. No award value, funding allocation, set-aside designation, or site visit requirement is specified at this preliminary phase. Activity under this code remains sparse in the recent state and local procurement record; the Texas initiative appears to be among the first formal moves toward direct manufacturer engagement in state pharmacy procurement at scale.